Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Clinical Pharmacokinetics
Erschienen in: Clinical Pharmacokinetics 11/2020

25.05.2020 | Original Research Article

Prediction of Maternal and Fetal Pharmacokinetics of Dolutegravir and Raltegravir Using Physiologically Based Pharmacokinetic Modeling

verfasst von: Xiaomei I. Liu, Jeremiah D. Momper, Natella Y. Rakhmanina, Dionna J. Green, Gilbert J. Burckart, Tim R. Cressey, Mark Mirochnick, Brookie M. Best, John N. van den Anker, André Dallmann

Erschienen in: Clinical Pharmacokinetics | Ausgabe 11/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Predicting drug pharmacokinetics in pregnant women including placental drug transfer remains challenging. This study aimed to develop and evaluate maternal–fetal physiologically based pharmacokinetic models for two antiretroviral drugs, dolutegravir and raltegravir.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Taylor AW, Nesheim SR, Zhang X, Song R, Fitzharris LF, Lampe MA, et al. Estimated perinatal HIV infection among infants born in the United States, 2002–2013. JAMA Pediatr. 2017;171(5):435–42.PubMedPubMedCentral
2.
Nesheim SR, Fitzharris LF, Lampe MA, Gray KM. Reconsidering the number of women with HIV infection who give birth annually in the United States. Public Health Rep. 2018;133(6):637–43.PubMedPubMedCentral
3.
Nesheim S, Taylor A, Lampe MA, Kilmarx PH, Fitz Harris L, Whitmore S, et al. A framework for elimination of perinatal transmission of HIV in the United States. Pediatrics. 2012;130(4):738–44.PubMed
4.
Caritis SN, Bastian JR, Zhang H, Kalluri H, English D, England M, et al. An evidence-based recommendation to increase the dosing frequency of buprenorphine during pregnancy. Am J Obstet Gynecol. 2017;217(4):459.e1–6.
5.
Krishna R, East L, Larson P, Valiathan C, Deschamps K, Luk JA, et al. Atazanavir increases the plasma concentrations of 1200 mg raltegravir dose. Biopharm Drug Dispos. 2016;37(9):533–41.PubMed
6.
Rahangdale L, Cates J, Potter J, Badell ML, Seidman D, Miller ES, et al. Integrase inhibitors in late pregnancy and rapid HIV viral load reduction. Am J Obstet Gynecol. 2016;214(3):385.e1–7.
7.
8.
9.
Dallmann A, Pfister M, Van Den Anker J, Eissing T. Physiologically based pharmacokinetic modeling in pregnancy: a systematic review of published models. Clin Pharmacol Ther. 2018;104(6):1110–24.PubMed
10.
Yap CW. PaDEL-descriptor: an open source software to calculate molecular descriptors and fingerprints. J Comput Chem. 2011;32(7):1466–74.PubMed
11.
Dallmann A, Solodenko J, Ince I, Eissing T. Applied concepts in PBPK modeling: how to extend an open systems pharmacology model to the special population of pregnant women. CPT Pharmacomet Syst Pharmacol. 2018;7(7):419–31.
12.
Reese MJ, Savina PM, Generaux GT, Tracey H, Humphreys JE, Kanaoka E, et al. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos. 2013;41(2):353–61.PubMed
13.
Dallmann A, Ince I, Meyer M, Willmann S, Eissing T, Hempel G. Gestation-specific changes in the anatomy and physiology of healthy pregnant women: an extended repository of model parameters for physiologically based pharmacokinetic modeling in pregnancy. Clin Pharmacokinet. 2017;56(11):1303–30.PubMed
14.
Dallmann A, Ince I, Coboeken K, Eissing T, Hempel G. A physiologically based pharmacokinetic model for pregnant women to predict the pharmacokinetics of drugs metabolized via several enzymatic pathways. Clin Pharmacokinet. 2018;57(6):749–68.PubMed
15.
Mian P, Van Den Anker JN, Van Calsteren K, Annaert P, Tibboel D, Pfister M, et al. Physiologically based pharmacokinetic modeling to characterize acetaminophen pharmacokinetics and N-acetyl-p-benzoquinone imine (NAPQI) formation in non-pregnant and pregnant women. Clin Pharmacokinet. 2020;59(1):97–110. https://​doi.​org/​10.​1007/​s40262-019-00799-5.CrossRefPubMed
16.
17.
Castellino S, Moss L, Wagner D, Borland J, Song I, Chen S, et al. Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans. Antimicrob Agents Chemother. 2013;57(8):3536–46.PubMedPubMedCentral
18.
Dooley KE, Sayre P, Borland J, Purdy E, Chen S, Song I, et al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr. 2013;62(1):21–7.PubMed
19.
Song IH, Borland J, Savina PM, Chen S, Patel P, Wajima T, et al. Pharmacokinetics of single-dose dolutegravir in HIV-seronegative subjects with moderate hepatic impairment compared to healthy matched controls. Clin Pharmacol Drug Dev. 2013;2(4):342–8.PubMedPubMedCentral
20.
Song I, Weller S, Patel J, Borland J, Wynne B, Choukour M, et al. Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation. Eur J Clin Pharmacol. 2016;72(6):665–70.PubMedPubMedCentral
21.
Song I, Borland J, Chen S, Patel P, Wajima T, Peppercorn A, et al. Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir. Antimicrob Agents Chemother. 2012;56(3):1627–9.PubMedPubMedCentral
22.
Weller S, Borland J, Chen S, Johnson M, Savina P, Wynne B, et al. Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment. Eur J Clin Pharmacol. 2014;70(1):29–35.PubMed
23.
Ford SL, Gould E, Chen S, Margolis D, Spreen W, Crauwels H, et al. Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744. Antimicrob Agents Chemother. 2013;57(11):5472–7.PubMedPubMedCentral
24.
Johnson M, Borland J, Chen S, Savina P, Wynne B, Piscitelli S. Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir. Br J Clin Pharmacol. 2014;78(5):1043–9.PubMedPubMedCentral
25.
Wang X, Cerrone M, Ferretti F, Castrillo N, Maartens G, Mcclure M, et al. Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin. Int J Antimicrob Agents. 2019;54(2):202–6.PubMed
26.
Min S, Song I, Borland J, Chen S, Lou Y, Fujiwara T, et al. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother. 2010;54(1):254–8.PubMed
27.
Kassahun K, Mcintosh I, Cui D, Hreniuk D, Merschman S, Lasseter K, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos. 2007;35(9):1657–63.PubMed
28.
Laufer R, Paz OG, Di Marco A, Bonelli F, Monteagudo E, Summa V, et al. Quantitative prediction of human clearance guiding the development of raltegravir (MK-0518, isentress) and related HIV integrase inhibitors. Drug Metab Dispos. 2009;37(4):873–83.PubMed
29.
Mulligan N, Best BM, Wang J, Capparelli EV, Stek A, Barr E, et al. Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV. AIDS. 2018;32(6):729–37.PubMedPubMedCentral
30.
Watts DH, Stek A, Best BM, Wang J, Capparelli EV, Cressey TR, et al. Raltegravir pharmacokinetics during pregnancy. J Acquir Immune Defic Syndr. 2014;67(4):375–81.PubMedPubMedCentral
31.
Waitt C, Orrell C, Walimbwa S, Singh Y, Kintu K, Simmons B, et al. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: a randomised trial (DolPHIN-1 study). PLoS Med. 2019;16(9):e1002895.PubMedPubMedCentral
32.
Blonk MI, Colbers AP, Hidalgo-Tenorio C, Kabeya K, Weizsacker K, Haberl AE, et al. Raltegravir in HIV-1-infected pregnant women: pharmacokinetics, safety, and efficacy. Clin Infect Dis. 2015;61(5):809–16.PubMed
33.
Dallmann A, Ince I, Solodenko J, Meyer M, Willmann S, Eissing T, et al. Physiologically based pharmacokinetic modeling of renally cleared drugs in pregnant women. Clin Pharmacokinet. 2017;56(12):1525–41.PubMed
34.
Zhang Z, Unadkat JD. Development of a novel maternal–fetal physiologically based pharmacokinetic model II: verification of the model for passive placental permeability drugs. Drug Metab Dispos. 2017;45(8):939–46.PubMedPubMedCentral
35.
Griessinger JA, Hauptstein S, Laffleur F, Netsomboon K, Bernkop-Schnurch A. Evaluation of the impact of multivalent metal ions on the permeation behavior of dolutegravir sodium. Drug Dev Ind Pharm. 2016;42(7):1118–26.PubMed
36.
Moss DM, Kwan WS, Liptrott NJ, Smith DL, Siccardi M, Khoo SH, et al. Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir. Antimicrob Agents Chemother. 2011;55(2):879–87.PubMed
37.
38.
Poulin P, Schoenlein K, Theil FP. Prediction of adipose tissue: plasma partition coefficients for structurally unrelated drugs. J Pharm Sci. 2001;90(4):436–47.PubMed
39.
Poulin P, Theil FP. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J Pharm Sci. 2002;91(1):129–56.PubMed
40.
Rodgers T, Leahy D, Rowland M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci. 2005;94(6):1259–76.PubMed
41.
Rodgers T, Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci. 2006;95(6):1238–57.PubMed
42.
Takaku T, Nagahori H, Sogame Y, Takagi T. Quantitative structure-activity relationship model for the fetal–maternal blood concentration ratio of chemicals in humans. Biol Pharm Bull. 2015;38(6):930–4.PubMed
43.
Nishimura M, Yaguti H, Yoshitsugu H, Naito S, Satoh T. Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi. 2003;123(5):369–75.PubMed
44.
Kawade N, Onishi S. The prenatal and postnatal development of UDP-glucuronyltransferase activity towards bilirubin and the effect of premature birth on this activity in the human liver. Biochem J. 1981;196(1):257–60.PubMedPubMedCentral
45.
Collier AC, Thevenon AD, Goh W, Hiraoka M, Kendal-Wright CE. Placental profiling of UGT1A enzyme expression and activity and interactions with preeclampsia at term. Eur J Drug Metab Pharmacokinet. 2015;40(4):471–80.PubMed
46.
47.
Jeong H, Choi S, Song JW, Chen H, Fischer JH. Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination. Xenobiotica. 2008;38(1):62–75.PubMedPubMedCentral
48.
Dallmann A, Liu XI, Burckart GJ, Van Den Anker J. Drug transporters expressed in the human placenta and models for studying maternal–fetal drug transfer. J Clin Pharmacol. 2019;59(Suppl. 1):S70–81.PubMedPubMedCentral
49.
Pfrunder A, Gutmann H, Beglinger C, Drewe J. Gene expression of CYP3A4, ABC-transporters (MDR1 and MRP1-MRP5) and hPXR in three different human colon carcinoma cell lines. J Pharm Pharmacol. 2003;55(1):59–66.PubMed
50.
Nakumura T, Sakaeda T, Ohmoto N, Moriya Y, Komoto C, Shirakawa T, et al. Gene expression profiles of ABC transporters and cytochrome P450 3A in Caco-2 and human colorectal cancer cell lines. Pharm Res. 2003;20(2):324–7.PubMed
51.
Zrieki A, Farinotti R, Buyse M. Cyclooxygenase inhibitors down regulate P-glycoprotein in human colorectal Caco-2 cell line. Pharm Res. 2008;25(9):1991–2001.PubMed
52.
Yano K, Shimizu S, Tomono T, Ogihara T. Gastrointestinal hormone cholecystokinin increases P-glycoprotein membrane localization and transport activity in Caco-2 cells. J Pharm Sci. 2017;106(9):2650–6.PubMed
53.
Sun M, Kingdom J, Baczyk D, Lye SJ, Matthews SG, Gibb W. Expression of the multidrug resistance P-glycoprotein, (ABCB1 glycoprotein) in the human placenta decreases with advancing gestation. Placenta. 2006;27(6–7):602–9.PubMed
54.
Wang C, Li H, Luo C, Li Y, Zhang Y, Yun D, et al. The effect of maternal obesity on the expression and functionality of placental P-glycoprotein: implications in the individualized transplacental digoxin treatment for fetal heart failure. Placenta. 2015;36(10):1138–47.PubMed
55.
Bataille A, Rousset J, Marret E, Bonnet F. Ultrasonographic evaluation of gastric content during labour under epidural analgesia: a prospective cohort study. Br J Anaesth. 2014;112(4):703–7.PubMed
56.
Davison JS, Davison MC, Hay DM. Gastric emptying time in late pregnancy and labour. J Obstet Gynaecol Br Commonw. 1970;77(1):37–41.PubMed
57.
Whitehead EM, Smith M, Dean Y, O’sullivan G. An evaluation of gastric emptying times in pregnancy and the puerperium. Anaesthesia. 1993;48(1):53–7.PubMed
58.
Stillhart C, Vucicevic K, Augustijns P, Basit AW, Batchelor H, Flanagan TR, et al. Impact of gastrointestinal physiology on drug absorption in special populations: an UNGAP review. Eur J Pharm Sci. 2020;147:105280.PubMed
59.
De Sousa MM, Hirt D, Vinot C, Valade E, Lui G, Pressiat C, et al. Prediction of human fetal pharmacokinetics using ex vivo human placenta perfusion studies and physiologically based models. Br J Clin Pharmacol. 2016;81(4):646–57.
60.
Schalkwijk S, Buaben AO, Freriksen JJM, Colbers AP, Burger DM, Greupink R, et al. Prediction of fetal darunavir exposure by integrating human ex-vivo placental transfer and physiologically based pharmacokinetic modeling. Clin Pharmacokinet. 2018;57(6):705–16.PubMed
61.
Liu XI, Momper JD, Rakhmanina N, Van Den Anker JN, Green DJ, Burckart GJ, et al. Physiologically based pharmacokinetic models to predict maternal pharmacokinetics and fetal exposure to emtricitabine and acyclovir. J Clin Pharmacol. 2020;60(2):240–55.PubMed
62.
Schalkwijk S, Greupink R, Colbers AP, Wouterse AC, Verweij VG, Van Drongelen J, et al. Placental transfer of the HIV integrase inhibitor dolutegravir in an ex vivo human cotyledon perfusion model. J Antimicrob Chemother. 2016;71(2):480–3.PubMed
63.
Hill MD, Abramson FP. The significance of plasma protein binding on the fetal/maternal distribution of drugs at steady-state. Clin Pharmacokinet. 1988;14(3):156–70.PubMed
64.
Chignell CF, Vesell ES, Starkweather DK, Berlin CM. The binding of sulfaphenazole to fetal, neonatal, and adult human plasma albumin. Clin Pharmacol Ther. 1971;12(6):897–901.PubMed
65.
Krasner J, Giacoia GP, Yaffe SJ. Drug–protein binding in the newborn infant. Ann N Y Acad Sci. 1973;226:101–14.PubMed
66.
Herve F, Rajkowski K, Martin MT, Dessen P, Cittanova N. Drug-binding properties of rat alpha 1-foetoprotein: binding of warfarin, phenylbutazone, azapropazone, diazepam, digitoxin and cholic acid. Biochem J. 1984;221(2):401–6.PubMedPubMedCentral
67.
Hirano K, Watanabe Y, Adachi T, Ito Y, Sugiura M. Drug-binding properties of human alpha-foetoprotein. Biochem J. 1985;231(1):189–91.PubMedPubMedCentral
68.
69.
70.
Zamek-Gliszczynski MJ, Zhang X, Mudunuru J, Du Y, Chen JL, Taskar KS, et al. Clinical extrapolation of the effects of dolutegravir and other HIV integrase inhibitors on folate transport pathways. Drug Metab Dispos. 2019;47(8):890–8.PubMed
71.
Moss DM, Siccardi M, Murphy M, Piperakis MM, Khoo SH, Back DJ, et al. Divalent metals and pH alter raltegravir disposition in vitro. Antimicrob Agents Chemother. 2012;56(6):3020–6.PubMedPubMedCentral
72.
Moss DM, Siccardi M, Back DJ, Owen A. Predicting intestinal absorption of raltegravir using a population-based ADME simulation. J Antimicrob Chemother. 2013;68(7):1627–34.PubMed
73.
Iwamoto M, Wenning LA, Petry AS, Laethem M, De Smet M, Kost JT, et al. Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2008;52(12):4338–433.PubMedPubMedCentral
74.
Iwamoto M, Wenning LA, Petry AS, Laethem M, De Smet M, Kost JT, et al. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharmacol Ther. 2008;83(2):293–9.PubMed
75.
Markowitz M, Morales-Ramirez JO, Nguyen BY, Kovacs CM, Steigbigel RT, Cooper DA, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2006;43(5):509–15.PubMed
76.
Rhee EG, Rizk ML, Brainard DM, Gendrano IN 3rd, Jin B, Wenning LA, et al. A pharmacokinetic comparison of adult and paediatric formulations of raltegravir in healthy adults. Antivir Ther. 2014;19(6):619–24.PubMed
77.
Wenning LA, Hanley WD, Brainard DM, Petry AS, Ghosh K, Jin B, et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2009;53(7):2852–6.PubMedPubMedCentral
78.
Iwamoto M, Wenning LA, Nguyen BY, Teppler H, Moreau AR, Rhodes RR, et al. Effects of omeprazole on plasma levels of raltegravir. Clin Infect Dis. 2009;48(4):489–92.PubMed
79.
Brainard DM, Friedman EJ, Jin B, Breidinger SA, Tillan MD, Wenning LA, et al. Effect of low-, moderate-, and high-fat meals on raltegravir pharmacokinetics. J Clin Pharmacol. 2011;51(3):422–7.PubMed
80.
Taburet AM, Sauvageon H, Grinsztejn B, Assuied A, Veloso V, Pilotto JH, et al. Pharmacokinetics of raltegravir in HIV-infected patients on rifampicin-based antitubercular therapy. Clin Infect Dis. 2015;61(8):1328–35.PubMed
Metadaten
Titel
Prediction of Maternal and Fetal Pharmacokinetics of Dolutegravir and Raltegravir Using Physiologically Based Pharmacokinetic Modeling
verfasst von
Xiaomei I. Liu
Jeremiah D. Momper
Natella Y. Rakhmanina
Dionna J. Green
Gilbert J. Burckart
Tim R. Cressey
Mark Mirochnick
Brookie M. Best
John N. van den Anker
André Dallmann
Publikationsdatum
25.05.2020
Verlag
Springer International Publishing
Erschienen in
Clinical Pharmacokinetics / Ausgabe 11/2020
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI
https://doi.org/10.1007/s40262-020-00897-9

Weitere Artikel der Ausgabe 11/2020

Clinical Pharmacokinetics 11/2020 Zur Ausgabe

Original Research Article

Population Pharmacokinetic–Pharmacodynamic Relationships of Sarilumab Using Disease Activity Score 28-Joint C-Reactive Protein and Absolute Neutrophil Counts in Patients with Rheumatoid Arthritis

Research Letter

Low Bioavailability of Oral Tacrolimus Suspension in Pediatric Kidney Transplant Patients

Original Research Article

Population Modelling of Dexmedetomidine Pharmacokinetics and Haemodynamic Effects After Intravenous and Subcutaneous Administration

Review Article

Maintenance Immunosuppression in Solid Organ Transplantation: Integrating Novel Pharmacodynamic Biomarkers to Inform Calcineurin Inhibitor Dose Selection

Review Article

Converging Generic Drug Product Development: Bioequivalence Design and Reference Product Selection

Original Research Article

Metabolism and Pharmacokinetic Drug–Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies